Skip to content

A Prospective, Randomized Controlled Trial to Assess the Efficacy and Safety of Plasma-Activated Water (PAW) Produced by the Plasma Vaginal Irrigator (WOMEN CARE) for the Inhibition of Human Papillomavirus (HPV)

A Prospective, Randomized Controlled Trial to Assess the Efficacy and Safety of Plasma-Activated Water (PAW) Produced by the Plasma Vaginal Irrigator (WOMEN CARE) for the Inhibition of Human Papillomavirus (HPV)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0011358
Enrollment
54
Registered
2025-12-19
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device, Procedure/Surgery : (1) Control Group - Follow-up from screening visit (Day 0) to assessment visits (2 and 4 months) (2) Experimental group - Three treatment sessions using the medi

Sponsors

Hanyang University Guri Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Aged 19 years or order 2) Persistent high-risk HPV infection of the cervix and vagina confirmed by two positive results at 3-month intervlas 3) Those who voluntarily agreed to participate in this clinical study and to provide written informed conset

Exclusion criteria

Exclusion criteria: 1) Those who are pregnant 2) Participants who are unable to maintain the lithotomy position 3) Other cases where participation in this clinical study is deemed unsuitable at the discretion of the researcher

Design outcomes

Primary

MeasureTime frame
Proportion of participants with a semi-quantitative reduction in HPV PCR levels

Secondary

MeasureTime frame
Proportion of participants with a semi-quantitative reduction in HPV PCR levels;Proportion of participants with conversion to HPV PCR negativity;Proportion of participants with conversion to HPV PCR negativity;Changes in PCR test results for 12 STIs;Adverse events / Serious adverse events

Countries

Korea, Republic of

Contacts

Public ContactUn Suk Jung

Hanyang University Guri Hospital

petrow@naver.com+82-31-560-2340

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026